TY - JOUR
T1 - International Dermoscopy Society consensus recommendations for the management of lentigo maligna
AU - Forsea, Ana-maria
AU - Pampena, Riccardo
AU - Akay, Bengu Nisa
AU - Apalla, Zoe
AU - Argenziano, Giuseppe
AU - Briatico, Giulia
AU - Braun, Ralph
AU - Cabo, Horacio
AU - Cabrera, Raul
AU - Carrera, Cristina
AU - Cinotti, Elisa
AU - Conforti, Claudio
AU - Errichetti, Enzo
AU - Ferrara, Gerardo
AU - Giuffrida, Roberta
AU - Guida, Stefania
AU - Guitera, Pascale
AU - Halpern, Allan C.
AU - Heyes, Stephen
AU - Hofmann-wellenhof, Rainer
AU - Hong, Angela M.
AU - Jaimes, Natalia
AU - Karls, Raimonds
AU - Kittler, Harald
AU - Kranke, Teresa
AU - Liopyris, Konstantinos
AU - Liu, Jie
AU - Longo, Caterina
AU - Malvehy, Josep
AU - Marghoob, Ashfaq A.
AU - Moneib, Hoda
AU - Moreno Ramirez, David
AU - Moscarella, Elvira
AU - Nagore, Eduardo
AU - Navarrete-dechent, Cristian
AU - Paoli, John
AU - Pellacani, Giovanni
AU - Peris, Ketty
AU - Puig, Susana
AU - Rosendahl, Cliff
AU - Rudnicka, Lidia
AU - Sadek, Ahmed
AU - Saiag, Philippe
AU - Salerni, Gabriel
AU - Scope, Alon
AU - Soyer, Hans Peter
AU - Starace, Michela V.
AU - Stolz, Wilhelm
AU - Swanson, David L.
AU - Thomas, Luc
AU - Tschandl, Philipp
AU - Zalaudek, Iris
AU - Lallas, Aimilios
N1 - © 2026 The Author(s). Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
PY - 2026/3/19
Y1 - 2026/3/19
N2 - Lentigo maligna (LM) is a subtype of cutaneous melanoma in situ that develops on chronically sun-damaged skin in elderly individuals. Its diagnosis and management remain challenging due to its slow progression, frequent occurrence on cosmetically sensitive areas in frail individuals, and tendency for subclinical peripheral extension. Despite its potential for invasive transformation, the natural history of LM remains incompletely understood and evidence-based management strategies for this specific entity remain limited. This work aims to bridge the gap between scarce high-quality evidence and the clinicians' need for practical guidance on LM management by formulating evidence-based and expert consensus-driven recommendations for diagnosis, treatment and follow-up. Under the coordination of the International Dermoscopy Society, a global, multidisciplinary consortium of 53 experts-including dermatologists, dermato-oncologists, dermatologic surgeons, radiologists, radiotherapists, pathologists and epidemiologists-formulated recommendations through structured consensus, informed by a comprehensive review of current scientific evidence and clinical practice standards. Optimal management of LM requires accurate diagnosis and individualized treatment planning. Non-invasive skin imaging techniques, especially dermoscopy and reflectance confocal microscopy, aid in diagnosis, biopsy orientation, lesion delineation and post-treatment monitoring. Multiple partial biopsies help confirm diagnosis and rule out invasion. Complete surgical excision remains the first treatment option. No definitive safety margins can be recommended for standard surgery; margin-controlled techniques are preferable for large or ill-defined lesions. Topical imiquimod and radiotherapy are effective alternatives where surgery is unsuitable. Topical imiquimod is useful as primary, adjuvant or neoadjuvant therapy. Blind destructive methods should be avoided. Close clinical and imaging follow-up is needed. Patient-centred care, shared decision-making, and a multidisciplinary approach are critical for optimal outcomes. These international consensus recommendations summarize current best practices for LM management, offering practical, evidence-informed guidance to clinicians while acknowledging the potential of future research in refining these conclusions.
AB - Lentigo maligna (LM) is a subtype of cutaneous melanoma in situ that develops on chronically sun-damaged skin in elderly individuals. Its diagnosis and management remain challenging due to its slow progression, frequent occurrence on cosmetically sensitive areas in frail individuals, and tendency for subclinical peripheral extension. Despite its potential for invasive transformation, the natural history of LM remains incompletely understood and evidence-based management strategies for this specific entity remain limited. This work aims to bridge the gap between scarce high-quality evidence and the clinicians' need for practical guidance on LM management by formulating evidence-based and expert consensus-driven recommendations for diagnosis, treatment and follow-up. Under the coordination of the International Dermoscopy Society, a global, multidisciplinary consortium of 53 experts-including dermatologists, dermato-oncologists, dermatologic surgeons, radiologists, radiotherapists, pathologists and epidemiologists-formulated recommendations through structured consensus, informed by a comprehensive review of current scientific evidence and clinical practice standards. Optimal management of LM requires accurate diagnosis and individualized treatment planning. Non-invasive skin imaging techniques, especially dermoscopy and reflectance confocal microscopy, aid in diagnosis, biopsy orientation, lesion delineation and post-treatment monitoring. Multiple partial biopsies help confirm diagnosis and rule out invasion. Complete surgical excision remains the first treatment option. No definitive safety margins can be recommended for standard surgery; margin-controlled techniques are preferable for large or ill-defined lesions. Topical imiquimod and radiotherapy are effective alternatives where surgery is unsuitable. Topical imiquimod is useful as primary, adjuvant or neoadjuvant therapy. Blind destructive methods should be avoided. Close clinical and imaging follow-up is needed. Patient-centred care, shared decision-making, and a multidisciplinary approach are critical for optimal outcomes. These international consensus recommendations summarize current best practices for LM management, offering practical, evidence-informed guidance to clinicians while acknowledging the potential of future research in refining these conclusions.
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=medunigraz_woslite&SrcAuth=WosAPI&KeyUT=WOS:001718121100001&DestLinkType=FullRecord&DestApp=WOS_CPL
U2 - 10.1111/jdv.70406
DO - 10.1111/jdv.70406
M3 - Guideline, consensus or position paper
C2 - 41854120
SN - 0926-9959
JO - Journal of the European Academy of Dermatology and Venereology
JF - Journal of the European Academy of Dermatology and Venereology
ER -